Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes

Russell P. Bowler, Sean Jacobson, Charmion Cruickshank, Grant J. Hughes, Charlotte Siska, Daniel S. Ory, Irina Petrache, Jean E. Schaffer, Nichole Reisdorph, Katerina Kechris

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) occurs in a minority of smokers and is characterized by intermittent exacerbations and clinical subphenotypes such as emphysema and chronic bronchitis. Although sphingolipids as a class are implicated in the pathogenesis of COPD, the particular sphingolipid species associated with COPD subphenotypes remain unknown. Objectives: To use mass spectrometry to determine which plasma sphingolipids are associated with subphenotypes of COPD. Methods: One hundred twenty-nine current and former smokers from the COPDGene cohort had 69 distinct sphingolipid species detected in plasma by targeted mass spectrometry. Of these, 23 were also measured in 131 plasma samples (117 independent subjects) using an untargeted platform in an independent laboratory. Regression analysis with adjustment for clinical covariates, correction for false discovery rate, and metaanalysis were used to test associations between COPD subphenotypes and sphingolipids. Peripheral blood mononuclear cells were used to test associations between sphingolipid gene expression and plasma sphingolipids. Measurements and Main Results: Of the measured plasma sphingolipids, five sphingomyelins were associated with emphysema; four trihexosylceramides and three dihexosylceramides were associated with COPD exacerbations. Three sphingolipids were strongly associated with sphingolipid gene expression, and 15 sphingolipid gene/metabolite pairs were differentially regulated between COPD cases and control subjects. Conclusions: There is evidence of systemic dysregulation of sphingolipid metabolism in patients with COPD. Subphenotyping suggests that sphingomyelins are strongly associated with emphysema and glycosphingolipids are associated with COPD exacerbations.

Original languageEnglish
Pages (from-to)275-284
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume191
Issue number3
DOIs
StatePublished - Feb 1 2015

Fingerprint

Sphingolipids
Chronic Obstructive Pulmonary Disease
Phenotype
Emphysema
Sphingomyelins
Trihexosylceramides
Disease Progression
Mass Spectrometry
Gene Expression
Glycosphingolipids
Chronic Bronchitis
Blood Cells
Regression Analysis

Keywords

  • Ceramides
  • Emphysema
  • Genomics
  • Metabolomics
  • Sphingomyelins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Bowler, R. P., Jacobson, S., Cruickshank, C., Hughes, G. J., Siska, C., Ory, D. S., ... Kechris, K. (2015). Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. American Journal of Respiratory and Critical Care Medicine, 191(3), 275-284. https://doi.org/10.1164/rccm.201410-1771OC

Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. / Bowler, Russell P.; Jacobson, Sean; Cruickshank, Charmion; Hughes, Grant J.; Siska, Charlotte; Ory, Daniel S.; Petrache, Irina; Schaffer, Jean E.; Reisdorph, Nichole; Kechris, Katerina.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 191, No. 3, 01.02.2015, p. 275-284.

Research output: Contribution to journalArticle

Bowler, RP, Jacobson, S, Cruickshank, C, Hughes, GJ, Siska, C, Ory, DS, Petrache, I, Schaffer, JE, Reisdorph, N & Kechris, K 2015, 'Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes', American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 3, pp. 275-284. https://doi.org/10.1164/rccm.201410-1771OC
Bowler, Russell P. ; Jacobson, Sean ; Cruickshank, Charmion ; Hughes, Grant J. ; Siska, Charlotte ; Ory, Daniel S. ; Petrache, Irina ; Schaffer, Jean E. ; Reisdorph, Nichole ; Kechris, Katerina. / Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. In: American Journal of Respiratory and Critical Care Medicine. 2015 ; Vol. 191, No. 3. pp. 275-284.
@article{ab51f8e21c2541e292e559392f410e05,
title = "Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes",
abstract = "Rationale: Chronic obstructive pulmonary disease (COPD) occurs in a minority of smokers and is characterized by intermittent exacerbations and clinical subphenotypes such as emphysema and chronic bronchitis. Although sphingolipids as a class are implicated in the pathogenesis of COPD, the particular sphingolipid species associated with COPD subphenotypes remain unknown. Objectives: To use mass spectrometry to determine which plasma sphingolipids are associated with subphenotypes of COPD. Methods: One hundred twenty-nine current and former smokers from the COPDGene cohort had 69 distinct sphingolipid species detected in plasma by targeted mass spectrometry. Of these, 23 were also measured in 131 plasma samples (117 independent subjects) using an untargeted platform in an independent laboratory. Regression analysis with adjustment for clinical covariates, correction for false discovery rate, and metaanalysis were used to test associations between COPD subphenotypes and sphingolipids. Peripheral blood mononuclear cells were used to test associations between sphingolipid gene expression and plasma sphingolipids. Measurements and Main Results: Of the measured plasma sphingolipids, five sphingomyelins were associated with emphysema; four trihexosylceramides and three dihexosylceramides were associated with COPD exacerbations. Three sphingolipids were strongly associated with sphingolipid gene expression, and 15 sphingolipid gene/metabolite pairs were differentially regulated between COPD cases and control subjects. Conclusions: There is evidence of systemic dysregulation of sphingolipid metabolism in patients with COPD. Subphenotyping suggests that sphingomyelins are strongly associated with emphysema and glycosphingolipids are associated with COPD exacerbations.",
keywords = "Ceramides, Emphysema, Genomics, Metabolomics, Sphingomyelins",
author = "Bowler, {Russell P.} and Sean Jacobson and Charmion Cruickshank and Hughes, {Grant J.} and Charlotte Siska and Ory, {Daniel S.} and Irina Petrache and Schaffer, {Jean E.} and Nichole Reisdorph and Katerina Kechris",
year = "2015",
month = "2",
day = "1",
doi = "10.1164/rccm.201410-1771OC",
language = "English",
volume = "191",
pages = "275--284",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes

AU - Bowler, Russell P.

AU - Jacobson, Sean

AU - Cruickshank, Charmion

AU - Hughes, Grant J.

AU - Siska, Charlotte

AU - Ory, Daniel S.

AU - Petrache, Irina

AU - Schaffer, Jean E.

AU - Reisdorph, Nichole

AU - Kechris, Katerina

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Rationale: Chronic obstructive pulmonary disease (COPD) occurs in a minority of smokers and is characterized by intermittent exacerbations and clinical subphenotypes such as emphysema and chronic bronchitis. Although sphingolipids as a class are implicated in the pathogenesis of COPD, the particular sphingolipid species associated with COPD subphenotypes remain unknown. Objectives: To use mass spectrometry to determine which plasma sphingolipids are associated with subphenotypes of COPD. Methods: One hundred twenty-nine current and former smokers from the COPDGene cohort had 69 distinct sphingolipid species detected in plasma by targeted mass spectrometry. Of these, 23 were also measured in 131 plasma samples (117 independent subjects) using an untargeted platform in an independent laboratory. Regression analysis with adjustment for clinical covariates, correction for false discovery rate, and metaanalysis were used to test associations between COPD subphenotypes and sphingolipids. Peripheral blood mononuclear cells were used to test associations between sphingolipid gene expression and plasma sphingolipids. Measurements and Main Results: Of the measured plasma sphingolipids, five sphingomyelins were associated with emphysema; four trihexosylceramides and three dihexosylceramides were associated with COPD exacerbations. Three sphingolipids were strongly associated with sphingolipid gene expression, and 15 sphingolipid gene/metabolite pairs were differentially regulated between COPD cases and control subjects. Conclusions: There is evidence of systemic dysregulation of sphingolipid metabolism in patients with COPD. Subphenotyping suggests that sphingomyelins are strongly associated with emphysema and glycosphingolipids are associated with COPD exacerbations.

AB - Rationale: Chronic obstructive pulmonary disease (COPD) occurs in a minority of smokers and is characterized by intermittent exacerbations and clinical subphenotypes such as emphysema and chronic bronchitis. Although sphingolipids as a class are implicated in the pathogenesis of COPD, the particular sphingolipid species associated with COPD subphenotypes remain unknown. Objectives: To use mass spectrometry to determine which plasma sphingolipids are associated with subphenotypes of COPD. Methods: One hundred twenty-nine current and former smokers from the COPDGene cohort had 69 distinct sphingolipid species detected in plasma by targeted mass spectrometry. Of these, 23 were also measured in 131 plasma samples (117 independent subjects) using an untargeted platform in an independent laboratory. Regression analysis with adjustment for clinical covariates, correction for false discovery rate, and metaanalysis were used to test associations between COPD subphenotypes and sphingolipids. Peripheral blood mononuclear cells were used to test associations between sphingolipid gene expression and plasma sphingolipids. Measurements and Main Results: Of the measured plasma sphingolipids, five sphingomyelins were associated with emphysema; four trihexosylceramides and three dihexosylceramides were associated with COPD exacerbations. Three sphingolipids were strongly associated with sphingolipid gene expression, and 15 sphingolipid gene/metabolite pairs were differentially regulated between COPD cases and control subjects. Conclusions: There is evidence of systemic dysregulation of sphingolipid metabolism in patients with COPD. Subphenotyping suggests that sphingomyelins are strongly associated with emphysema and glycosphingolipids are associated with COPD exacerbations.

KW - Ceramides

KW - Emphysema

KW - Genomics

KW - Metabolomics

KW - Sphingomyelins

UR - http://www.scopus.com/inward/record.url?scp=84922308684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922308684&partnerID=8YFLogxK

U2 - 10.1164/rccm.201410-1771OC

DO - 10.1164/rccm.201410-1771OC

M3 - Article

C2 - 25494452

AN - SCOPUS:84922308684

VL - 191

SP - 275

EP - 284

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -